Stoke Therapeutics (STOK) Interest Expenses (2020 - 2026)
Stoke Therapeutics' (STOK) quarterly Interest Expenses came in at $23000.0 in Q1 2026, up 2200.0% year-on-year from $1000.0 in Q1 2025, and down 97.9% quarter-over-quarter from $1.1 million in Q4 2025.
Stoke Therapeutics (STOK) Interest Expenses (2020 - 2026) Analysis & Trends
Stoke Therapeutics' Interest Expenses history runs 7 years deep, the most recent figure standing at $23000.0 for Q1 2026.
- On a quarterly basis, Interest Expenses rose 2200.0% year-over-year to $23000.0 in Q1 2026; TTM through Mar 2026 was $1.1 million, a 43.9% increase from a year earlier, with the FY2025 full-year figure at $184.4 million, up 802.85% from the prior year.
- Interest Expenses retreated to $23000.0 in Q1 2026 per STOK's latest filing, from $1.1 million in the prior quarter.
- Across five years, Interest Expenses topped out at $133.3 million in Q4 2023 and bottomed at $1000.0 in Q1 2025.
- The 5-year median for Interest Expenses is $728500.0 (2022), against an average of $15.8 million.
- Across the five-year window, Interest Expenses sank 99.88% in 2024 and surged 116440.0% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $97.9 million in 2022, then jumped by 36.17% to $133.3 million in 2023, then slumped by 99.42% to $773000.0 in 2024, then soared by 41.53% to $1.1 million in 2025, then tumbled by 97.9% to $23000.0 in 2026.
- Per Business Quant, the three latest STOK Interest Expenses figures stand at $23000.0 (Q1 2026), $1.1 million (Q4 2025), and $3000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | 23,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2026 | 23,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 5.83 Mn |
| Jun 30, 2025 | 5.83 Mn |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Dec 31, 2024 | 773,000.00 |
| Dec 31, 2024 | 773,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Dec 31, 2023 | 133.31 Mn |
| Dec 31, 2023 | 133.31 Mn |
| Sep 30, 2023 | 172,000.00 |
| Sep 30, 2023 | 172,000.00 |